Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Trametinib for KRAS-Mutant Solid Tumors
NCT06962254Phase 1Recruiting
- Sponsor
- China Medical University Hospital
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imatinib and trametinib in solid tumor, sponsored by China Medical University Hospital. Primary endpoint: Overall Response Rate at 2 years. Started May 2025; status: recruiting.
02
Drugs
imatinibtrametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06962254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962254.